Valuation: Cytomedix, Inc.

Market Cap 48.41M 42.08M 39.17M 35.96M 67.91M 4.62B 68.96M 462M 181M 2.3B 182M 178M 7.71B P/E 2024
-27.4x
P/E 2025 -37.1x
Enterprise Value 48.46M 42.12M 39.21M 36M 67.98M 4.63B 69.03M 462M 181M 2.3B 182M 178M 7.72B EV / Sales 2024
47,922,901x
EV / Sales 2025 28,658,774x
Free-Float
42.1%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 63 2016-01-07
Chief Operating Officer 60 2014-03-29
Director TitleAgeSince
Director/Board Member 69 2009-01-29
Chairman 63 2012-02-06
Director/Board Member 67 2016-05-04
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -0.13%-3.79%+35.87%+154.81% 25.98B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2024 2025
Net sales 1.37 1.19 1.1 1.01 1.92 130.32 1.94 13.02 5.11 64.88 5.13 5.01 217.55 3.31 2.88 2.68 2.46 4.65 316.31 4.72 31.6 12.4 157.47 12.44 12.17 528.03
Net income -2.32M -2.02M -1.88M -1.73M -3.26M -222M -3.31M -22.16M -8.7M -110M -8.73M -8.54M -370M -2.51M -2.18M -2.03M -1.87M -3.52M -240M -3.58M -23.96M -9.4M -119M -9.43M -9.23M -400M
Net Debt -120K -104K -96.7K -88.78K -168K -11.41M -170K -1.14M -447K -5.68M -449K -439K -19.04M 48.4K 42.07K 39.16K 35.96K 67.9K 4.62M 68.95K 462K 181K 2.3M 182K 178K 7.71M
Logo Cytomedix, Inc.
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.
Employees
-